查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933904

按产品类型、手术类型、材料、最终用户和临床适应症分類的血管重建器械市场—全球预测，2026-2032年

Revascularization Device Market by Product Type, Procedure Type, Material, End User, Clinical Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，再灌注设备市场价值将达到 25.7 亿美元，到 2026 年将成长至 28.3 亿美元，到 2032 年将达到 51.2 亿美元，年复合成长率为 10.30%。

关键市场统计数据
基准年 2025 25.7亿美元
预计年份：2026年 28.3亿美元
预测年份 2032 51.2亿美元
复合年增长率 (%) 10.30%

日益增长的临床、监管和技术压力如何重塑现代医疗路径中再灌注装置的研发和临床应用

再灌注器材领域正处于不断发展的临床实践、技术改进和不断变化的监管重点的交汇点。临床医生越来越倾向于采用微创方法，以减少手术创伤并保持血管完整性，而器械开发商则透过改进支架平台、生物可吸收支架和辅助导管技术来响应这一需求，这些技术强调输送性和长期血管癒合。同时，支付方的严格审查和以价值为导向的医疗模式也对製造商和医疗系统提出了挑战，要求他们证明其产品能够提供持续的临床疗效和具有成本效益的治疗方案。

材料科学的进步、影像导引手术以及不断扩大的门诊护理正在共同重新定义设备创新重点和临床应用模式。

再灌注装置领域正经历变革性的转变，这得益于材料科学的突破、手术技术的进步以及对以患者为中心的治疗效果日益增长的需求。聚合物化学和金属合金工程的进步使得支架结构更加纤细，药物释放型动力学更可预测，进而影响血管再阻塞情况和血管癒合。同时，血管内影像和生理评估的整合正在改变外科医生规划和实施手术的方式，推动决策模式从单纯依赖血管造影术转向精准引导下的支架放置和尺寸选择。

关税驱动的供应链重组和近岸外包措施导致设备製造商的营运中断和策略采购重新评估。

2025年，美国关税的累积影响相关人员带来了新的商业性复杂性。关税加剧了采购和库存计划的成本压力，迫使製造商重新评估其筹资策略，并在免税地区寻找替代供应商。因此，许多机构开始着手绘製供应链图，以识别关税风险，并优先考虑与全球供应商重新谈判合约。

为什么将产品、流程、材料、最终用户和适应症细分整合到您的商业化策略中对于临床应用和持续相关性至关重要

细分市场分析揭示了按产品类型、最终用户、手术类型、材料和临床适应症分類的各类产品，其开发和商业化路径各不相同。产品类型分类包括动脉粥状硬化斑块切除术装置、球囊血管成形术导管、裸金属支架、药物涂层球囊、药物释放型支架和血管支架。药物释放型支架又细分为依Everolimus洗脱支架、Sirolimus洗脱支架、西罗莫司洗脱支架和佐他莫司洗脱支架，每个亚组都有其独特的临床权衡和监管过程，这些都会影响其市场推广路径。以最终用户划分，器械的使用模式主要集中在门诊手术中心、医院和专科医疗中心，这些管道对物流和采购的要求各不相同，从而影响产品设计和支援模式。

美洲、欧洲、中东和非洲以及亚太地区的区域监管、临床和商业性趋势如何影响市场进入和推广路径，并针对每个市场量身定制这些路径。

区域趋势对临床实践模式、监管路径和商业化策略有着显着影响，美洲、欧洲、中东和非洲以及亚太地区各有其独特的策略要务。在美洲，成熟的介入性心臟病学网络和整合的支付系统强调强有力的临床证据和已证实的价值，製造商通常优先考虑广泛的上市后监测和临床医生培训项目，以支持产品在医院和门诊渠道的持续应用。而在欧洲和中东及非洲地区，由于监管环境的多样性和报销机制的不均衡，需要更精细的市场进入策略，以适应各国采购惯例实践和区域临床指南的差异。

再灌注装置的竞争优势源自于整合研发、持续的临床证据以及降低市场进入门槛的策略伙伴关係。

血管重建器材领域的竞争格局由成熟的平台供应商、专业创新企业和垂直整合供应商组成，它们各自在器材设计、实证医学证据产生和医疗服务提供者合作方面采取差异化策略。现有企业倾向于逐步改善平台、拓展临床适应症，并提供包括技术培训和长期监测计画在内的综合服务。同时，专业创新企业则优先开发材料创新、新型药物释放型基质和手术辅助器械，旨在解决尚未满足的临床挑战，例如复杂病变形态和高出血风险患者群体。

为医疗设备製造商提供切实可行的策略性倡议，以加速产品推广应用、增强市场韧性，并建立符合医疗机构临床和支付方期望的证据。

产业领导者应优先考虑一系列切实可行的措施，使产品开发与临床实际情况和商业性需求保持一致。首先，加快转化医学项目，将材料优化与具有临床意义的终点指标和可操作的註册研究设计相结合，以产生能够引起介入医师和支付方共鸣的证据。其次，透过近岸外包和关键零件的多通路筹资策略，投资供应链韧性，同时维持严格的变更管理流程，以最大限度地减少监管摩擦。第三，制定针对最终使用者环境的商业化方案，针对每个部署情境（门诊手术中心、医院和专科医疗中心）设计训练、包装和支援方法。

采用严谨的混合方法，结合临床医生访谈、监管和临床文献的综合分析以及供应链分析，以形成可操作的见解和检验的细分框架。

本研究结合了对临床医生、采购专业人员和行业高管的定性访谈，并辅以对同行评审文献、监管文件和临床註册资料进行的二次分析，以确保证据的全面性。访谈重点在于手术流程、装置选择标准和术后追踪实践，而二次分析则着重于材料性能特征、监管指导文件以及已发表的安全性和有效性文献。调查方法强调多资讯来源验证，以检验主题结论并减少单一资讯来源偏差。

整合临床、技术和商业性的必要因素，以确定将器材创新转化为持续临床影响的策略重点。

总之，再灌注装置领域正经历技术快速进步、临床工作流程不断演变以及对长期价值日益增长的需求。材料创新、影像整合以及门诊手术的普及正在改变装置的设计、评估和使用方式。供应链中断和关税压力凸显了稳健筹资策略的重要性以及组件采购的实际影响，而监管和支付框架的区域差异则要求制定适应性强的市场进入计划。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的血管重建器械市场

  • 动脉粥状硬化斑块切除术装置
  • 球囊血管成形术导管
  • 裸金属支架
  • 药物涂层球囊
  • 药物释放型支架
    • Everolimus洗脱支架
    • 紫杉醇洗脱支架
    • Sirolimus洗脱支架
    • 佐他莫司洗脱支架
  • 血管支架

9. 依手术方式分類的血管重建器械市场

  • 冠状动脉绕道手术手术
  • 经皮冠状动脉介入治疗

第十章 血管再生设备市场（依材料划分）

  • 生物可吸收支架
  • 由金属製成
    • 钴铬
    • 铂金铬
    • 不銹钢
  • 聚合物
    • 生物可吸收聚合物
    • 不可生物降解聚合物

第十一章 依最终用户分類的血管重建器械市场

  • 门诊手术中心
  • 医院
  • 专业医疗中心

第十二章 依疾病分類的血管重建器械市场

  • 急性冠状动脉症候群
  • 血管再阻塞
  • 稳定性冠状动脉疾病

第十三章 区域性血管重建器械市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 血管重建器械市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国血管重建器械市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国血管重建器械市场

第十七章：中国血管再生设备市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AngioDynamics, Inc.
  • Asahi Intecc Co., Ltd.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Getinge AB
  • iVascular SLU
  • Johnson & Johnson
  • Lepu Medical Technology（Beijing）Co., Ltd
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Company Limited
  • Penumbra, Inc.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: MRR-C36616F699B7

The Revascularization Device Market was valued at USD 2.57 billion in 2025 and is projected to grow to USD 2.83 billion in 2026, with a CAGR of 10.30%, reaching USD 5.12 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.57 billion
Estimated Year [2026] USD 2.83 billion
Forecast Year [2032] USD 5.12 billion
CAGR (%) 10.30%

How converging clinical, regulatory, and technological pressures are reshaping revascularization device development and clinical adoption across contemporary care pathways

The revascularization devices landscape sits at the intersection of evolving clinical practice, technological refinement, and shifting regulatory priorities. Clinicians increasingly favor minimally invasive approaches that reduce procedural trauma while preserving vessel integrity, and device innovators respond with refined stent platforms, bioabsorbable scaffolds, and adjunctive catheter technologies that emphasize deliverability and long-term vessel healing. Concurrently, payer scrutiny and value-based care initiatives prompt manufacturers and health systems to demonstrate durable clinical outcomes and cost-effective pathways.

In this context, multidisciplinary teams are adapting pathways that blend interventional cardiology expertise with advanced imaging and adjunctive therapies to optimize patient selection and procedural outcomes. As a result, product development priorities have migrated from incremental mechanical improvements toward integrated systems that consider material composition, drug elution profiles, and procedural efficiency. Regulatory agencies have intensified focus on real-world safety data and post-market surveillance, driving manufacturers to incorporate robust evidence-generation plans into their clinical development strategies.

Taken together, these dynamics create a responsive but complex environment in which new entrants must navigate clinical credibility, supply chain resilience, and health-economics signaling. Therefore, stakeholders are increasingly prioritizing translational evidence, clinical partnerships, and strategic commercialization pathways to convert innovation into sustainable clinical adoption and durable patient benefit.

Material science improvements, imaging-guided procedures, and outpatient care expansion are collectively redefining device innovation priorities and clinical utilization patterns

The revascularization device landscape is undergoing transformative shifts driven by a combination of material science breakthroughs, procedural technique evolution, and heightened demand for patient-centric outcomes. Advances in polymer chemistry and metallic alloy engineering have enabled thinner strut profiles and more predictable drug-elution kinetics, which in turn influence restenosis profiles and vessel healing. Meanwhile, the integration of intravascular imaging and physiologic assessment is changing how operators plan and execute interventions, prompting a move away from angiography-alone decision making toward precision-guided placement and sizing.

At the same time, the rise of ambulatory surgical centers and outpatient procedural pathways is encouraging device manufacturers to design systems optimized for simplified logistics, shorter procedure times, and reduced anesthesia requirements. Concurrently, iterative improvements in atherectomy and balloon technologies are expanding the procedural toolkit for complex lesion preparation, facilitating the use of contemporary stents and scaffolds in anatomies that were previously challenging. Collectively, these shifts foster a more patient-centered approach that privileges device performance in realistic clinical settings, and they require manufacturers to align product portfolios with evolving care delivery models and clinician preferences for evidence-backed innovations.

Furthermore, reimbursement and regulatory expectations are increasingly tethered to demonstrable long-term safety and economic value, prompting a surge in registries and pragmatic trials. As a result, organizations that can bridge bench advances with robust clinical evidence and efficient commercial strategies will maintain competitive advantage in this rapidly adapting environment.

Tariff-driven supply chain realignment and nearshoring initiatives created operational disruption and strategic procurement recalibrations across device manufacturers

In 2025, the cumulative effects of tariff measures in the United States introduced a new layer of commercial complexity for revascularization device stakeholders who rely on global supply chains for components, raw materials, and finished goods. Tariff measures amplified cost pressure across procurement and inventory planning, prompting manufacturers to reassess sourcing strategies and to explore alternative suppliers in tariff-exempt jurisdictions. As a consequence, many organizations initiated supply-chain mapping exercises to identify tariff exposure points and to prioritize contractual renegotiations with global vendors.

Operationally, the tariffs accelerated conversations about nearshoring and supplier diversification. Several manufacturers pursued incremental localization of critical manufacturing steps, particularly for metallic substrates and polymer processing, to reduce exposure to cross-border levies and associated lead-time volatility. Simultaneously, procurement teams increased focus on total landed cost analyses that incorporate tariff liabilities, customs clearance complexities, and potential disruption risks. Importantly, while tariffs affected transactional cost dynamics, clinical adoption decisions continued to hinge on safety, efficacy, and long-term outcomes, meaning that commercial repositioning required careful communication to payers and providers about any product or packaging changes.

In parallel, regulatory filings and quality documentation underwent closer scrutiny when supply chain changes were implemented, since component substitutions and manufacturing site shifts can trigger additional regulatory interactions. Thus, tariffs contributed to a strategic rebalancing across procurement, quality, regulatory, and commercial functions, emphasizing resilience and transparency in supplier relationships and manufacturing plans.

Why integrating product, procedural, material, end-user, and indication segmentation into commercialization strategies is critical for clinical uptake and sustained relevance

Segmentation analysis reveals distinct pathways for product development and commercialization across categories defined by product type, end user, procedure type, material, and clinical indication. Based on Product Type, the landscape is organized around Atherectomy Devices, Balloon Angioplasty Catheters, Bare-Metal Stents, Drug-Coated Balloons, Drug-Eluting Stents, and Vascular Scaffolds, with the Drug-Eluting Stents cohort further subdivided into Everolimus-Eluting Stents, Paclitaxel-Eluting Stents, Sirolimus-Eluting Stents, and Zotarolimus-Eluting Stents, each subgroup presenting unique clinical trade-offs and regulatory histories that influence adoption pathways. Based on End User, device utilization patterns concentrate in Ambulatory Surgical Center, Hospital, and Specialty Center settings, and these channels impose different logistical and purchasing requirements that affect product design and support models.

Based on Procedure Type, stakeholders must align product claims and training efforts to the clinical nuances of Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention, as procedural complexity and operator workflows diverge significantly between surgical revascularization and catheter-based approaches. Based on Material, device performance and long-term vessel response are shaped by choices among Bioabsorbable Scaffold, Metallic, and Polymer compositions, with Metallic constructs further differentiated by Cobalt-Chromium, Platinum-Chromium, and Stainless Steel alloys, and Polymer options distinguished between Bioresorbable Polymer and Non-Biodegradable Polymer approaches that carry distinct healing and surveillance considerations. Based on Clinical Indication, device selection is influenced by the clinical presentation, whether Acute Coronary Syndrome, Restenosis, or Stable Coronary Artery Disease, and these indications drive both procedural urgency and evidence expectations.

Taken together, the segmentation framework highlights that a one-size-fits-all commercialization strategy is unlikely to succeed. Instead, targeted development plans that account for clinical context, material science implications, and health system purchasing behavior will be essential to achieve clinical uptake and to sustain long-term relevance in varied care settings.

How region-specific regulatory, clinical, and commercial dynamics in the Americas, Europe Middle East & Africa, and Asia-Pacific shape tailored market access and adoption pathways

Regional dynamics exert powerful influence on clinical practice patterns, regulatory pathways, and commercialization approaches, with distinct strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, established interventional cardiology networks and consolidated payer systems emphasize robust clinical evidence and value demonstration, and manufacturers often prioritize extensive post-market studies and clinician training programs to support durable adoption across hospital and outpatient channels. Conversely, in Europe, Middle East & Africa, diverse regulatory frameworks and heterogeneous reimbursement landscapes require more nuanced market access strategies that adapt to country-level procurement conventions and regional clinical guideline variations.

In the Asia-Pacific region, rapid infrastructural investments in tertiary care and increasing procedural volumes create fertile ground for scalable deployment, yet manufacturers must tailor product portfolios to local clinical preferences, cost sensitivities, and regulatory timelines. Moreover, cross-border partnerships and capacity-building initiatives often accelerate adoption when local champions and opinion leaders validate new device paradigms. Throughout these regions, connectivity among supply chain considerations, clinical evidence generation, and commercialization execution remains central. Therefore, organizations that calibrate clinical data programs, regulatory submissions, and commercial support to each region's specific operating environment will be better positioned to translate innovation into consistent clinical use and operational sustainability.

Competitive positioning in revascularization devices rewards integrated R&D, clinical evidence alignment, and strategic partnerships that lower adoption barriers

The competitive landscape in revascularization devices is populated by established platform providers, specialized innovators, and a cadre of vertically integrated suppliers, each pursuing differentiated strategies in device design, evidence generation, and provider engagement. Incumbent organizations often focus on incremental platform improvements, expanded clinical indications, and bundled service offerings that include technical training and long-term surveillance programs. In contrast, specialized innovators prioritize material innovation, novel drug-elution matrices, and procedural adjuncts that seek to resolve unmet clinical challenges such as complex lesion morphology or high-bleeding-risk populations.

Across the competitive set, strategic partnerships between device developers and technology providers-particularly in imaging, data analytics, and remote proctoring-have emerged as a key vector for differentiation. These alliances facilitate combined value propositions that address both procedural efficacy and operational efficiency. Moreover, the interplay between intellectual property strength, manufacturing footprint, and regulatory acumen determines how rapidly organizations can translate laboratory advances into clinical availability. Consequently, competitive advantage increasingly accrues to entities that synchronize R&D pipelines with robust clinical programs and pragmatic commercialization models that reduce adoption friction for providers.

Practical strategic initiatives for device manufacturers to accelerate adoption, enhance resilience, and align evidence with clinical and payer expectations across care settings

Industry leaders should prioritize a set of actionable initiatives that align product development with clinical realities and commercial imperatives. First, accelerate translational programs that combine material optimization with clinically meaningful endpoints and pragmatic registry designs to generate evidence that resonates with interventionalists and payers. Second, invest in supply chain resilience through nearshoring or multi-sourcing strategies for critical components while maintaining rigorous change-control processes to minimize regulatory friction. Third, tailor commercialization playbooks to end-user settings by designing training, packaging, and support modalities specifically for Ambulatory Surgical Center, Hospital, and Specialty Center adoption scenarios.

In addition, embed imaging and physiologic guidance into product value narratives to demonstrate how devices integrate into precision-guided procedural workflows. Align clinical indication planning to address Acute Coronary Syndrome, Restenosis, and Stable Coronary Artery Disease use cases with distinct evidence strategies and post-market surveillance commitments. Finally, pursue selective regional approaches that account for regulatory and payer landscapes in the Americas, Europe, Middle East & Africa, and Asia-Pacific, leveraging local clinical champions and adaptive reimbursement strategies to facilitate market entry and sustained utilization. By implementing these initiatives, organizations can reduce time-to-adoption, enhance clinician confidence, and create compelling value propositions for diverse stakeholder groups.

A rigorous mixed-methods approach combining clinician interviews, regulatory and clinical literature synthesis, and supply-chain analysis to produce actionable insights and validated segmentation frameworks

This research synthesized primary qualitative interviews with clinicians, procurement specialists, and industry executives, supplemented by secondary source analysis of peer-reviewed literature, regulatory documents, and clinical registry outputs to ensure a comprehensive evidence base. Primary interviews focused on procedural workflow, device selection criteria, and post-procedural follow-up practices, while secondary analysis emphasized material performance characteristics, regulatory guidance documents, and published safety and efficacy literature. The methodology emphasized triangulation across sources to validate thematic conclusions and to reduce single-source bias.

Data curation and categorization adhered to rigorous inclusion criteria for clinical relevance and methodological transparency. Device categorizations and segmentation frameworks were developed in consultation with clinical advisors to ensure that product, material, procedural, and indication groupings reflected current practice patterns. Furthermore, supply chain and commercial impact assessments were informed by procurement and operations interviews, enabling a practical view of tariff and sourcing implications. Analytical limitations included potential regional variability in data availability and the evolving nature of post-market evidence, which were addressed through targeted sensitivity checks and iterative review with subject-matter experts. Overall, the approach combined depth of clinical insight with operational and commercial analysis to produce actionable conclusions for stakeholders.

Synthesis of clinical, technological, and commercial imperatives that define strategic priorities for converting device innovation into durable clinical impact

In conclusion, the revascularization device environment is characterized by rapid technical refinement, evolving clinical workflows, and intensified demands for demonstrable long-term value. Material innovations, imaging integration, and outpatient procedural expansion are reshaping how devices are designed, evaluated, and utilized. Supply-chain perturbations and tariff-related pressures have underscored the importance of resilient procurement strategies and the operational implications of component sourcing, while regional differences in regulatory and payer frameworks necessitate adaptive market access plans.

Therefore, stakeholders who synchronize product innovation with pragmatic evidence programs, robust quality and regulatory planning, and targeted commercialization tactics will be best positioned to succeed. Emphasizing clinician collaboration, selective regional prioritization, and transparent communication about safety and performance will facilitate adoption and foster trust among providers and payers alike. As the field continues to evolve, organizations that internalize these priorities and maintain nimble execution will convert technological advances into sustained clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Revascularization Device Market, by Product Type

  • 8.1. Atherectomy Devices
  • 8.2. Balloon Angioplasty Catheters
  • 8.3. Bare-Metal Stents
  • 8.4. Drug-Coated Balloons
  • 8.5. Drug-Eluting Stents
    • 8.5.1. Everolimus-Eluting Stents
    • 8.5.2. Paclitaxel-Eluting Stents
    • 8.5.3. Sirolimus-Eluting Stents
    • 8.5.4. Zotarolimus-Eluting Stents
  • 8.6. Vascular Scaffolds

9. Revascularization Device Market, by Procedure Type

  • 9.1. Coronary Artery Bypass Grafting
  • 9.2. Percutaneous Coronary Intervention

10. Revascularization Device Market, by Material

  • 10.1. Bioabsorbable Scaffold
  • 10.2. Metallic
    • 10.2.1. Cobalt-Chromium
    • 10.2.2. Platinum-Chromium
    • 10.2.3. Stainless Steel
  • 10.3. Polymer
    • 10.3.1. Bioresorbable Polymer
    • 10.3.2. Non-Biodegradable Polymer

11. Revascularization Device Market, by End User

  • 11.1. Ambulatory Surgical Center
  • 11.2. Hospital
  • 11.3. Specialty Center

12. Revascularization Device Market, by Clinical Indication

  • 12.1. Acute Coronary Syndrome
  • 12.2. Restenosis
  • 12.3. Stable Coronary Artery Disease

13. Revascularization Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Revascularization Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Revascularization Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Revascularization Device Market

17. China Revascularization Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AngioDynamics, Inc.
  • 18.7. Asahi Intecc Co., Ltd.
  • 18.8. B. Braun Melsungen AG
  • 18.9. Becton, Dickinson and Company
  • 18.10. Biotronik SE & Co. KG
  • 18.11. Boston Scientific Corporation
  • 18.12. Cardinal Health, Inc.
  • 18.13. Cook Medical LLC
  • 18.14. Edwards Lifesciences Corporation
  • 18.15. Getinge AB
  • 18.16. iVascular SLU
  • 18.17. Johnson & Johnson
  • 18.18. Lepu Medical Technology (Beijing) Co., Ltd
  • 18.19. Medtronic plc
  • 18.20. Merit Medical Systems, Inc.
  • 18.21. MicroPort Scientific Corporation
  • 18.22. OrbusNeich Medical Company Limited
  • 18.23. Penumbra, Inc.
  • 18.24. Stryker Corporation
  • 18.25. Teleflex Incorporated
  • 18.26. Terumo Corporation
  • 18.27. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL REVASCULARIZATION DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL REVASCULARIZATION DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ATHERECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ATHERECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ATHERECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BARE-METAL STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BARE-METAL STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BARE-METAL STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-COATED BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-COATED BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-COATED BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY EVEROLIMUS-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY EVEROLIMUS-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY EVEROLIMUS-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PACLITAXEL-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PACLITAXEL-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PACLITAXEL-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SIROLIMUS-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SIROLIMUS-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SIROLIMUS-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ZOTAROLIMUS-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ZOTAROLIMUS-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ZOTAROLIMUS-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY VASCULAR SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY VASCULAR SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY VASCULAR SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIOABSORBABLE SCAFFOLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIOABSORBABLE SCAFFOLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIOABSORBABLE SCAFFOLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY COBALT-CHROMIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY COBALT-CHROMIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY COBALT-CHROMIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PLATINUM-CHROMIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PLATINUM-CHROMIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PLATINUM-CHROMIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIORESORBABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIORESORBABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIORESORBABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY RESTENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY RESTENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY RESTENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 174. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 176. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 177. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 201. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 203. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 204. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 210. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 212. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 213. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 214. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)